Non-Small Cell Lung Carcinoma – Page 3

Nuvation Bio Advances with Pooled Data for ROS1-positive Lung Cancer Treatment, Eyes FDA Submission

9 months ago talkbio0Tagged Bio, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Nuvation, ROS1-positive, Submission, taletrectinib, TRUST-I, TRUST-II, United States Food and Drug Administration

Nuvation Bio, ROS1-positive NSCLC, taletrectinib, TRUST-I, TRUST-II, FDA submission, lung cancer treatment

Innovent Biologics Reports Promising Results in Early-Stage Study of Bispecific Antibody IBI363 in Lung Cancer Patients

9 months ago talkbio0Tagged Antibodies, Bispecific, Biological Factors, Early-Stage Study, IBI363, Innovent, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, PD-1/IL-2, α-bias

Innovent Biologics, IBI363, Bispecific Antibody, Lung Cancer, Early-Stage Study, PD-1/IL-2 α-bias, Non-Small Cell Lung Cancer (NSCLC)

AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms

9 months ago talkbio0Tagged AstraZeneca, Clinical Research, Daiichi, Dato-DXd, Datopotamab deruxtecan, Decision, Non-Small Cell Lung Carcinoma, Overall Survival, Sankyo, TROPION-Lung01, United States Food and Drug Administration

AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study

WCLC24: Rybrevant-Lazcluze Combination Shows Enhanced Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC

9 months ago talkbio0Tagged Benefit, Continuance of life, EGFR-mutated, first-line, Lazcluze, MARIPOSA, Non-Small Cell Lung Carcinoma, Rybrevant, Tagrisso, WCLC24

Rybrevant, Lazcluze, Tagrisso, EGFR-mutated NSCLC, MARIPOSA study, WCLC24, survival benefit, first-line treatment.

AstraZeneca Refines NSCLC Treatment Strategies with Biomarker-Driven Approaches

9 months ago talkbio0Tagged AstraZeneca, Biological Markers, Immunotherapy, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma

NSCLC, biomarkers, targeted therapy, immunotherapy, AstraZeneca, lung cancer treatment

AstraZeneca and Gilead Explore TROP2 ADCs in Lung Cancer, Seeking Pathways to Approval

9 months ago talkbio0Tagged ADCs, AstraZeneca, Datopotamab, Deruxtecan, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, TACSTD2 gene, Trodelvy

TROP2 ADCs, Lung Cancer, AstraZeneca, Gilead, Datopotamab Deruxtecan, Trodelvy, Non-Small Cell Lung Cancer (NSCLC)

Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Reducing Disease Progression Risk by 49%

9 months ago talkbio0Tagged Akeso, Ivonescimab, Keytruda, Non-Small Cell Lung Carcinoma, PD-L1, pembrolizumab, Phase 3 trial, Positive, summit

Ivonescimab, Keytruda, Non-Small Cell Lung Cancer (NSCLC), Phase 3 Trial, HARMONi-2, PD-L1 Positive, Pembrolizumab, Summit Therapeutics, Akeso.

Johnson & Johnson’s Rybrevant-Lazcluze Combination Shows Superior Survival Trend Over AstraZeneca’s Tagrisso in EGFR-Mutated Lung Cancer

9 months ago talkbio0Tagged amivantamab-vmjw, Chemotherapy-free, Clinical Research, EGFR-mutated lung cancer, Lazcluze, lazertinib, MARIPOSA, Non-Small Cell Lung Carcinoma, osimertinib, Rybrevant, Survival Analysis

Rybrevant (amivantamab-vmjw), Lazcluze (lazertinib), Tagrisso (osimertinib), EGFR-mutated lung cancer, Non-small cell lung cancer (NSCLC), MARIPOSA study, Survival analysis, Chemotherapy-free treatment